JPRN-UMIN000000501已完成2 期
Phase II Study of Docetaxel and TS-1 Combination Therapy for Outpatients with Relapsed or Refractory Non-small Cell Lung cancer - Phase II Study of Docetaxel and TS-1 Combination Therapy for Relapsed or Refractory Non-small Cell Lung Cancer
Outpatient Oncology Unit Kyoto University Hospital0 个研究点目标入组 40 人开始时间: 2006年10月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active ineterstitial pneumonitis 2) History of using TS-1 or docetaxel 3) Active infectious disease 4) Active hepatitis or hepatocirrhosis 5) Active concomitant malignancy 6) Uncontrollable diabetes 7) Serious cardiac disease 8) Psycologic illness 9) Other severe complications 10) Pleural or pericardial effusion, or ascites requiring treatment 11) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 12) Regular use of warfarin 13) Regular use of fenitoin or frucitocin 14) High fever 15) Clinical symptom of brain metastases 16) Serious nephropathy and/or edema 17) Regular use of steroid 18) Medical history of serious allergy reactions to any drug 19) Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
2 期
Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerMetastatic gastric cancer (Advanced or recurrent gastric cancer)JPRN-C000000103Hiroshima Cancer Therapy Development Organization (HiCTDO)50
已完成
1 期
Phase I/II Study of Docetaxel and S-1 Combination Therapy for Advanced Non-small Cell Lung CancerJPRN-C000000281The Tokyo Cooperative Oncology Group60
已完成
不适用
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
已完成
2 期
Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancerAdvanced or recurrent esophageal cancerJPRN-UMIN000005877Toho University43
进行中（未招募）
1 期
A phase I/II study of Docetaxel (Taxotere, TM), Cisplatinum and Capecitabine (Xeloda, TM) (TCX) in patients with advanced oesophago-gastric cancer. - TCXocally advanced or metastatic adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma of the oesophagus, oesophago-gastric junction or stomach.MedDRA version: 8.1 Level: LLT Classification code 10055102 Term: Oesophageal cancer metastaticEUCTR2006-002389-21-GBorth Wales NHS Trust80